Lotte Chilsung Beverage (005300) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Jun, 2026Executive summary
Q2 2025 consolidated sales declined 1.1% year-over-year to 10,873 billion KRW, with operating profit up 3.5% to 624 billion KRW and net profit rising 31.6% to 277 billion KRW.
1H 2025 consolidated sales fell 1.9% year-over-year to 19,976 billion KRW, operating profit dropped 9.9% to 874 billion KRW, and net profit decreased 10.9% to 332 billion KRW.
Achieved consolidated revenue of KRW 1,997.6 billion and operating income of KRW 87.4 billion for the half-year ended June 30, 2025.
Beverage and liquor segments experienced sales declines, while overseas subsidiaries posted strong growth in both sales and operating profit.
Overseas expansion, especially in the Philippines and Russia, contributed to sales growth.
Financial highlights
Q2 2025 gross profit margin decreased to 33.9% from 35.5% year-over-year.
Q2 2025 operating profit margin improved to 5.7% from 5.5% year-over-year.
Q2 2025 net profit margin increased to 2.6% from 1.9% year-over-year.
Gross margin for 1H 2025 was 33.2%, down from 34.7% YoY.
Cash and cash equivalents at period end: KRW 163.8 billion.
Outlook and guidance
2H 2025 strategy focuses on sustainable business model, infrastructure optimization, and technology adoption.
Full-year 2025 consolidated sales guidance is 43,100 billion KRW (+7.1% YoY), with operating profit expected at 2,400 billion KRW (+29.8% YoY), and OPM rising to 5.6%.
Beverage, liquor, and overseas segments all forecasted to grow in sales and operating profit, with overseas operating profit nearly doubling.
Focus on expanding zero-calorie and health-oriented beverage lines to capture market trends.
Targeting a 30% shareholder return rate by 2028, shifting from separate to consolidated basis.
Latest events from Lotte Chilsung Beverage
- Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 202423 Jun 2026 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 202423 Jun 2026 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 202523 Jun 2026 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 202523 Jun 2026 - Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 202622 Jun 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 20251 Apr 2026 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 20245 Jun 2025